The FDA has set a goal date of Aug. 27, 2025. If approved, the therapy would be branded as Lytenava and be the first ...

The US Food and Drug Administration (FDA) has accepted the resubmission of the Biologics License Application (BLA) for ...

"We are initiating a process to explore alternatives available to the company to maximize stockholder value, which include ...

John L. Marshall, MD, discusses the sequencing of targeted therapy for refractory metastatic colorectal cancer.

The FDA has approved Opdivo plus Yervoy for the first-line treatment of MSI-H/dMMR colorectal cancer, supported by the Phase ...

To optimize treatment outcomes for patients whose late-stage cancer shows resistance to the standard treatment, Sarasota Memorial Research Institute will participate in testing an experimental ...

Approval of the Opdivo plus Yervoy combination regimen was based on results from the Phase III CheckMate-8HW trial, which was ...

Patients in the pembrolizumab-olaparib arm had clinically meaningful improvements in PFS over patients in the control arm.

The FDA has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for unresectable or metastatic MSI-H/dMMR colorectal cancer.

Bevacizumab may be preferable to ranibizumab in the treatment of retinopathy of prematurity in as far as it is associated with a lower risk of retreatment.

The FDA has accepted for review a resubmission of the BLA for bevacizumab-vikg (ONS-5010) for the treatment of wet AMD.

Ahmedabad: Intas Pharma has announced the appointment of Parthiv Mehta as the new Vice President - Rest of Africa & International Fertility."We are delighted to welcome Parthiv Mehta as ...